Guardant Health Stock Soars Amid New Collaborations
Written by Emily J. Thompson, Senior Investment Analyst
Source: Fool
- Stock Performance: Guardant Health's stock has surged over the past six months, currently priced at $110.48 with a market cap of $14 billion, reflecting strong market confidence in its future growth potential.
- Collaboration Agreement: The company has signed a multi-year collaboration with Merck to develop companion diagnostics and market new cancer therapies using Guardant's Infinity Smart program, further solidifying its leadership in precision oncology.
- Positive Cash Flow: In Q3 2025, Guardant's core oncology business achieved positive free cash flow ahead of schedule, with management expecting to maintain this trend throughout 2026 and beyond, indicating significant operational efficiency improvements.
- FDA Approval: Guardant360 CDx received FDA approval as a companion diagnostic for Pfizer's Braftovi, marking its first FDA certification in colorectal cancer, which, while not impacting Q4 results, lays a solid foundation for future growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GH
Wall Street analysts forecast GH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GH is 124.69 USD with a low forecast of 105.00 USD and a high forecast of 155.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
18 Buy
1 Hold
0 Sell
Strong Buy
Current: 110.480
Low
105.00
Averages
124.69
High
155.00
Current: 110.480
Low
105.00
Averages
124.69
High
155.00
About GH
Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
GUARDANT HEALTH INC: UBS Increases Price Target from $110 to $175
- Price Increase Announcement: Cub's target price has been raised to $175 from the previous $110.
- Market Impact: This adjustment reflects a significant change in market expectations and valuation for Cub.
Continue Reading
Guardant Health's Optimistic Future Outlook
- Positive Financial Performance: Guardant Health achieved positive free cash flow in Q3 2025, one quarter ahead of its goal, indicating strong growth potential in its core oncology business, with expectations to maintain positive cash flow throughout 2026 and beyond, thereby boosting investor confidence.
- Strategic Collaboration Expansion: The company signed a multi-year collaboration with Merck to develop companion diagnostics and market new cancer therapies using Guardant's Infinity Smart program, further solidifying its market position in precision oncology.
- FDA Approval Milestone: Guardant360 CDx received FDA approval as a companion diagnostic for Pfizer's Braftovi and Eli Lilly's Erbitux in combination chemotherapy, marking its first FDA approval in colorectal cancer, enhancing the company's competitive edge in the market.
- Optimistic Market Outlook: Although the fourth-quarter financial results for 2025 have yet to be announced, investors maintain an optimistic view of Guardant Health's future, believing that the upcoming update could serve as a catalyst for stock price appreciation, although caution is advised against rushing into purchases in the short term.
Continue Reading